Bone-seeking radiopharmaceuticals have been used to effectively treat cancer arising from
and metastasizing to bone in humans and dogs. The rate of complete tumor control is low …

177 is currently being investigated as a potential agent for providing palliative care to the
patients suffering from bone pain due to metastatic skeletal carcinoma. The present article …

Radiochemical studies and biological evaluation in animal models have shown superior
radiochemical properties and better clearance pattern for 177 Lu-DOTMP compared with …

INTRODUCTION: Radionuclide therapy (RNT) is an effective method for bone pain palliation
in patients suffering from bone metastasis. Due to the long half-life, easy production and …

Use of bone‐seeking radiopharmaceuticals is an established modality in the palliative care
of pain due to skeletal metastases. 177Lu‐DOTMP is a promising radiopharmaceutical for …

Abstract Two new radiopharmaceuticals, 186 Re-1-hydroxyethylidenediphosphonate (186
Re-HEDP) and 153 Smethylenediaminetetramethylenephospho… (153 Sm-EDTMP), have …

177Lu is presently considered as an excellent radionuclide for developing bone pain
palliation agents owing to its suitable nuclear decay characteristics [T1/2= 6.73 d, Eβ (max) …

Background Designing ideal radiopharmaceuticals for use as bone pain palliative agents
requires the use of a moderate energy β− emitter as the radionuclide and a …

Objective: The objective of the present work was to develop a freeze-dried
ethylenediaminetetramethylene phosphonic acid (EDTMP) kit, suitable for the convenient …

INTRODUCTION: The therapeutic potential of the bone-seeking radiopharmaceutical
153Sm-labeled 1, 4, 7, 10-tetraazacyclododecanetetramethylenephos… acid (153Sm …